Frail Patients, Fans, Fingerprints and much more!
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 31 in our series The Oncology Journal Club.
This week’s episode is in our usual format and has so much detail squeezed into 34 minutes, with discussion of prominent papers, practice changing trials, Quick Bites and much more. Hans Prenen gets stuck into bispecific antibodies, Craig Underhill takes us through ASCO’s Report on Progress Against Cancer and Eva discusses Checkmate 577, a practice changing clinical trial exploring the role of adjuvant nivolumab in esophageal cancer.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Smith, S.M., et al. Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer. Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1165-1184. DOI: 10.1200/JCO.20.03420. Access online here.
- Sheridan C., et al. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254. doi: 10.1038/s41587-021-00850-6. PMID: 33692520. Access online here.
- Kingwell K. Bispecific antibodies catch cancer neoantigens. Nat Rev Drug Discov. 2021 Mar 30. doi: 10.1038/d41573-021-00062-2. Epub ahead of print. PMID: 33785902. Access online here.
- Kelly, R.J., et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384:1191-1203 DOI: 10.1056/NEJMoa2032125. Access online here.
This Week’s Quick Bites:
- Biller LH, et al. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106. Access online here.
- Hui, D., et al. Management of Dyspnea in Advanced Cancer: ASCO Guideline. Journal of Clinical Oncology DOI: 10.1200/JCO.20.03465. Published online February 22, 2021. Access online here.
- Thibaud, et al. Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study. Journal of Geriatric Oncology. Access online here.
- Park HJ, et al. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(3):e211136. doi:10.1001/jamanetworkopen.2021.1136 Access online here.
- MOGA position statement on COVID
Amazing Paper of the Week:
Dr Zachary Rubin @rubin_allergy
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
You can find Eva on Twitter here: @profevasegelov
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on Twitter here: @CraigUnderhill
Professor Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
You can find Hans on Twitter here: @HPrenen
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus